nach oben

Journal of Neural Transmission

Erschienen in:

01.01.2013 | Biological Psychiatry - Review article

Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB₁ receptor antagonists

verfasst von: E. Kirilly, L. Hunyady, G. Bagdy

Erschienen in: Journal of Neural Transmission | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

There is strong evidence that endocannabinoids modulate signaling of serotonin and noradrenaline, which play key roles in the pathophysiology and treatment of anxiety and depression. Most pharmacological and genetic, human and rodent studies suggest that the presence of under-functioning endocannabinoid type-1 (CB₁) receptors is associated with increased anxiety and elevated extracellular serotonin concentration. In contrast, noradrenaline is presumably implicated in the mediation of depression-type symptoms of CB₁ receptor antagonists. Evidence shows that most CB₁ receptors located on axons and terminals of GABA-ergic, serotonergic or glutamatergic neurons stimulate the activity of noradrenergic neurons. In contrast, those located on noradrenergic axons and terminals inhibit noradrenaline release efficiently. In this latter process, excitatory ionotropic or G protein-coupled receptors, such as the NMDA, alpha1 and beta1 adrenergic receptors, activate local endocannabinoid synthesis at postsynaptic sites and stimulate retrograde endocannabinoid neurotransmission acting on CB₁ receptors of noradrenergic terminals. The underlying mechanisms include calcium signal generation, which activates enzymes that increase the synthesis of both anandamide and 2-arachidonoylglycerol, while G_q/11 protein activation also increases the formation of 2-arachidonoylglycerol from diacylglycerol during the signaling process. In addition, other non-CB₁ receptor endocannabinoid targets such as CB₂, transient receptor potential vanilloid subtype, peroxisome proliferator-activated receptor-alpha and possibly GPR55 can also mediate some of the endocannabinoid effects. In conclusion, both neuronal activation and neurotransmitter release depend on the in situ synthesized endocannabinoids and thus, local endocannabinoid concentrations in different brain areas may be crucial in the net effect, namely in the regulation of neurons located postsynaptically to the noradrenergic synapse.

Adermark L, Lovinger DM (2007) Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proc Natl Acad Sci USA 104(51):20564–20569PubMedCrossRef

Aghajanian GK, Cedarbaum JM, Wang RY (1977) Evidence for norepinephrine-mediated collateral inhibition of locus coeruleus neurons. Brain Res 136(3):570–577PubMedCrossRef

Anand A, Charney DS (2000) Norepinephrine dysfunction in depression. J Clin Psychiatry 61(Suppl 10):16–24PubMed

Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160(1):1–12PubMedCrossRef

Ashton CH, Moore PB (2011) Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 124(4):250–261PubMedCrossRef

Aso E, Renoir T, Mengod G, Ledent C, Hamon M, Maldonado R, Lanfumey L, Valverde O (2009) Lack of CB1 receptor activity impairs serotonergic negative feedback. J Neurochem 109(3):935–944PubMedCrossRef

Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R, Akaoka H, Drolet G, Astier B et al (1991) Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 88:47–75PubMedCrossRef

Bagdy G (1998) Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences. Ann N Y Acad Sci 851:357–363PubMedCrossRef

Balazsa T, Biro J, Gullai N, Ledent C, Sperlagh B (2008) CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. Neurochem Int 52(1–2):95–102PubMedCrossRef

Baldwin DS, Evans DL, Hirschfeld RM, Kasper S (2002) Can we distinguish anxiety from depression? Psychopharmacol Bull 36(Suppl 2):158–165PubMed

Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27(43):11700–11711PubMedCrossRef

Bambico FR, Duranti A, Tontini A, Tarzia G, Gobbi G (2009) Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 15(14):1623–1646PubMedCrossRef

Barna I, Zelena D, Arszovszki AC, Ledent C (2004) The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 75(24):2959–2970PubMedCrossRef

Berridge CW, Waterhouse BD (2003) The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42(1):33–84PubMedCrossRef

Bertolino M, Vicini S, Gillis R, Travagli A (1997) Presynaptic alpha2-adrenoceptors inhibit excitatory synaptic transmission in rat brain stem. Am J Physiol 272(3 Pt 1):G654–G661PubMed

Blier P, Briley M (2011) The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatr Dis Treat 7(Suppl 1):15–20PubMed

Boehm S (1999) Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J Physiol 519(Pt 2):439–449PubMedCrossRef

Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, Paykel E, Versiani M, Racagni G (2002) The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 12(5):461–475PubMedCrossRef

Buffalari DM, Grace AA (2007) Noradrenergic modulation of basolateral amygdala neuronal activity: opposing influences of alpha-2 and beta receptor activation. J Neurosci 27(45):12358–12366PubMedCrossRef

Carvalho AF, Mackie K, Van Bockstaele EJ (2010) Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci 31(2):286–301PubMedCrossRef

Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386–389PubMedCrossRef

Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE (2010) Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 167(5):509–527PubMedCrossRef

Cedarbaum JM, Aghajanian GK (1977) Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol 44(4):375–385PubMedCrossRef

Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29(4):252–265PubMed

Christensen NJ, Vestergaard P, Sorensen T, Jerris AG, Rafaelsen OJ (1980) Cerebrospinal fluid adrenaline in endogenous depression. Lancet 1(8170):722PubMed

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370(9600):1706–1713PubMedCrossRef

Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grubler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U (2007) Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148(4):1574–1581PubMedCrossRef

Dahlstrom A, Fuxe K (1964) Localization of monoamines in the lower brain stem. Experientia 20(7):398–399PubMedCrossRef

De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW (1991) Brain beta-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment. Psychopharmacology 105(2):283–288PubMedCrossRef

De Paermentier F, Mauger JM, Lowther S, Crompton MR, Katona CL, Horton RW (1997) Brain alpha-adrenoceptors in depressed suicides. Brain Res 757(1):60–68PubMedCrossRef

Delgado PL (2000) Depression: the case for a monoamine deficiency. J Clin Psychiatry 61(Suppl 6):7–11PubMed

Delgado PL, Moreno FA (2000) Role of norepinephrine in depression. J Clin Psychiatry 61(Suppl 1):5–12PubMed

Dell’Osso B, Palazzo MC, Oldani L, Altamura AC (2011) The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther 17(6):723–732PubMedCrossRef

Denson TF, Earleywine M (2006) Decreased depression in marijuana users. Addict Behav 31(4):738–742PubMedCrossRef

Despres JP (2009) Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 15(5):553–570PubMedCrossRef

Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353(20):2121–2134PubMedCrossRef

Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H, Heindel W, Young R, Morris P, Arolt V, Deckert J, Suslow T, Baune BT (2008) Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18(10):751–759PubMedCrossRef

Drevets WC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11(2):240–249PubMedCrossRef

Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59(12):1116–1127PubMedCrossRef

FDA (2007) US Food and Drug Administration Advisory Committee. FDA briefi ng document: zimulti (rimonabant) Tablets, 20 mg http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm. Assessed Aug 6 2007

Filakovszky J, Gerber K, Bagdy G (1999) A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model. Neurosci Lett 261(1–2):89–92PubMedCrossRef

Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83(3):1017–1066PubMed

Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L (2001) 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21(20):8188–8197PubMed

Gjerris A (1988) Baseline studies on transmitter substances in cerebrospinal fluid in depression. Acta Psychiatr Scand Suppl 346:1–35PubMedCrossRef

Gonda X, Rihmer Z, Juhasz G, Zsombok T, Bagdy G (2007) High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res 149(1–3):261–266PubMedCrossRef

Gonda X, Fountoulakis KN, Juhasz G, Rihmer Z, Lazary J, Laszik A, Akiskal HS, Bagdy G (2009) Association of the s allele of the 5-HTTLPR with neuroticism-related traits and temperaments in a psychiatrically healthy population. Eur Arch Psychiatry Clin Neurosci 259(2):106–113PubMedCrossRef

Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54(1):129–141PubMedCrossRef

Graf M, Jakus R, Kantor S, Levay G, Bagdy G (2004) Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett 359(1–2):45–48PubMedCrossRef

Gruber AJ, Pope HG Jr, Brown ME (1996) Do patients use marijuana as an antidepressant? Depression 4(2):77–80PubMedCrossRef

Gyombolai P, Pap D, Turu G, Catt KJ, Bagdy G, Hunyady L (2012) Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. Mol Cell Endocrinol 353(1–2):29–36PubMedCrossRef

Haddjeri N, Blier P, de Montigny C (1998) Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18(23):10150–10156PubMed

Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, Freund TF (2000) Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12(9):3239–3249PubMedCrossRef

Halbach OvBu, Dermietzel R (eds) (2002) Neurotransmitters and neuromodulators: handbook of receptors and biological effects. Wiley-VCH, Weinheim

Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16(7):1395–1398PubMedCrossRef

Haring M, Marsicano G, Lutz B, Monory K (2007) Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146(3):1212–1219PubMedCrossRef

Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, Luchessi AD, Castro LM, Giorgi R, Rioli V, Ferro ES, Devi LA (2007) Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 104(51):20588–20593PubMedCrossRef

Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, Sanchez C, Waldhoer M (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25(11):1835–1848PubMedCrossRef

Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87(5):1932–1936PubMedCrossRef

Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11(2):563–583PubMed

Hill MN, Gorzalka BB (2005) Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 16(5–6):333–352PubMedCrossRef

Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ, Gorzalka BB (2008a) Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106(6):2322–2336PubMedCrossRef

Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008b) Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41(2):48–53PubMedCrossRef

Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G (2009a) The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30(9):484–493PubMedCrossRef

Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009b) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34(8):1257–1262PubMedCrossRef

Hirschfeld RM (2000) History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 61(Suppl 6):4–6PubMed

Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23(5):477–501PubMedCrossRef

Irving AJ, Rae MG, Coutts AA (2002) Cannabinoids on the brain. ScientificWorldJournal 2:632–648PubMedCrossRef

Juhasz G, Chase D, Pegg E, Downey D, Toth ZG, Stones K, Platt H, Mekli K, Payton A, Elliott R, Anderson IM, Deakin JF (2009) CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34(8):2019–2027PubMedCrossRef

Kahn RS, van Praag HM, Wetzler S, Asnis GM, Barr G (1988) Serotonin and anxiety revisited. Biol Psychiatry 23(2):189–208PubMedCrossRef

Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380PubMedCrossRef

Kantor S, Anheuer ZE, Bagdy G (2000) High social anxiety and low aggression in Fawn-Hooded rats. Physiol Behav 71(5):551–557PubMedCrossRef

Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26(21):5628–5637PubMedCrossRef

Kaufman J, Charney D (2000) Comorbidity of mood and anxiety disorders. Depress Anxiety 12(Suppl 1):69–76PubMedCrossRef

Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26(11):2991–3001PubMedCrossRef

Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105PubMedCrossRef

Kirilly E, Gonda X, Bagdy G (2012) CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol (Oxf) 205(1):41–60

Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105(7):2699–2704PubMedCrossRef

Lazary J, Lazary A, Gonda X, Benko A, Molnar E, Hunyady L, Juhasz G, Bagdy G (2009) Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. Am J Med Genet B Neuropsychiatr Genet 150B(8):1118–1127PubMedCrossRef

Lazary J, Juhasz G, Hunyady L, Bagdy G (2011) Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci 32(5):270–280PubMedCrossRef

Leonard BE (2000) Evidence for a biochemical lesion in depression. J Clin Psychiatry 61(Suppl 6):12–17PubMed

Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292):1527–1531PubMedCrossRef

Lovinger DM, Davis MI, Costa RM (2010) Endocannabinoid signaling in the striatum. In: Steiner H, Tseng KY (eds) Handbook of basal ganglia structure and function. Academic Press, London, pp 167–186CrossRef

Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168:299–325PubMedCrossRef

Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316(3):969–982PubMedCrossRef

Manta S, El Mansari M, Debonnel G, Blier P (2012) Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems. Int J Neuropsychopharmacol 17:1–12CrossRef

Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11(12):4213–4225PubMedCrossRef

Mato S, Aso E, Castro E, Martin M, Valverde O, Maldonado R, Pazos A (2007) CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem 103(5):2111–2120PubMedCrossRef

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564PubMedCrossRef

Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327(4):535–550PubMedCrossRef

McEwen BS (2005) Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54(5 Suppl 1):20–23PubMedCrossRef

Mendiguren A, Pineda J (2004) Cannabinoids enhance N-methyl-D-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. Neurosci Lett 363(1):1–5PubMedCrossRef

Mendiguren A, Pineda J (2006) Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 534(1–3):83–88PubMedCrossRef

Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wolfel B, Dodt HU, Zieglgansberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51(4):455–466PubMedCrossRef

Moore RY, Card JP (eds) (1984) Noradrenaline-containing neuron systems. Handbook of chemical neuroanatomy, vol 2. Elsevier, Amsterdam

Moreira FA, Crippa JA (2009) The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 31(2):145–153PubMedCrossRef

Moretti A, Gorini A, Villa RF (2003) Affective disorders, antidepressant drugs and brain metabolism. Mol Psychiatry 8(9):773–785PubMedCrossRef

Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, Pistis M (2006) Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci 23(9):2385–2394PubMedCrossRef

Nutt DJ (2002) The neuropharmacology of serotonin and noradrenaline in depression. Int Clin Psychopharmacol 17(Suppl 1):S1–S12PubMedCrossRef

O’Brien JT, Ames D, Schweitzer I, Colman P, Desmond P, Tress B (1996) Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer’s disease. Br J Psychiatry 168(6):679–687PubMedCrossRef

Olpe HR, Steinmann M (1991) Responses of locus coeruleus neurons to neuropeptides. Prog Brain Res 88:241–248PubMedCrossRef

Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514–536PubMedCrossRef

Oropeza VC, Mackie K, Van Bockstaele EJ (2007) Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 1127(1):36–44PubMedCrossRef

Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40(2):288–295PubMed

Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145(12):5431–5438PubMedCrossRef

Penninx BW, Beekman AT, Bandinelli S, Corsi AM, Bremmer M, Hoogendijk WJ, Guralnik JM, Ferrucci L (2007) Late-life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamo-pituitary-adrenal axis. Am J Geriatr Psychiatry 15(6):522–529PubMedCrossRef

Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL (2004) Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 46(1):115–125PubMedCrossRef

Poddar MK, Dewey WL (1980) Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 214(1):63–67PubMed

Reguero L, Puente N, Elezgarai I, Mendizabal-Zubiaga J, Canduela MJ, Buceta I, Ramos A, Suarez J, Rodriguez de Fonseca F, Marsicano G, Grandes P (2011) GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus. PLoS One 6(10):e26167PubMedCrossRef

Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl 1):2–19PubMedCrossRef

Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L (2008) Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 26(2):357–367PubMedCrossRef

Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152(7):1092–1101PubMedCrossRef

Samuels ER, Szabadi E (2008) Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part I: principles of functional organisation. Curr Neuropharmacol 6(3):235–253PubMedCrossRef

Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122(5):509–522PubMed

Stanley M, Mann JJ (1983) Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1(8318):214–216PubMedCrossRef

Suarez J, Bermudez-Silva FJ, Mackie K, Ledent C, Zimmer A, Cravatt BF, de Fonseca FR (2008) Immunohistochemical description of the endogenous cannabinoid system in the rat cerebellum and functionally related nuclei. J Comp Neurol 509(4):400–421PubMedCrossRef

Szemeredi K, Komoly S, Kopin IJ, Bagdy G, Keiser HR, Goldstein DS (1991) Simultaneous measurement of plasma and brain extracellular fluid concentrations of catechols after yohimbine administration in rats. Brain Res 542(1):8–14PubMedCrossRef

Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, Kita Y, Hashimoto K, Shimizu T, Watanabe M, Sakimura K, Kano M (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65(3):320–327PubMedCrossRef

To CT, Bagdy G (1999) Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 38(2):279–282PubMedCrossRef

Tsigos C, Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53(4):865–871PubMedCrossRef

Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83(2):393–411PubMedCrossRef

Turu G, Simon A, Gyombolai P, Szidonya L, Bagdy G, Lenkei Z, Hunyady L (2007) The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. J Biol Chem 282(11):7753–7757PubMedCrossRef

Turu G, Varnai P, Gyombolai P, Szidonya L, Offertaler L, Bagdy G, Kunos G, Hunyady L (2009) Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors. J Biol Chem 284(25):16914–16921PubMedCrossRef

Umathe SN, Manna SS, Jain NS (2011) Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice. Behav Brain Res 223(1):125–134PubMedCrossRef

Valverde O, Torrens M (2012) CB1 receptor-deficient mice as a model for depression. Neuroscience 204:193–206PubMedCrossRef

Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program. Diabetes Care 31(Suppl 2):S229–S240PubMedCrossRef

Van Waes V, Beverley JA, Siman H, Tseng KY, Steiner H (2012) CB1 cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation. Front Pharmacol 3:21PubMed

Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81(2):331–342PubMedCrossRef

Weiss JM, Stout JC, Aaron MF, Quan N, Owens MJ, Butler PD, Nemeroff CB (1994) Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res Bull 35(5–6):561–572PubMedCrossRef

WHO (2011) Depression. http://www.who.int/mental_health/management/depression/definition/en/

Williamson EM, Evans FJ (2000) Cannabinoids in clinical practice. Drugs 60(6):1303–1314PubMedCrossRef

Wittchen HU, Kessler RC, Pfister H, Lieb M (2000) Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl 406:14–23PubMedCrossRef

Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN (1990) 5HT2 receptor changes in major depression. Biol Psychiatry 27(5):489–496PubMedCrossRef

Titel: Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB1 receptor antagonists
verfasst von: E. Kirilly
L. Hunyady
G. Bagdy
Publikationsdatum: 01.01.2013
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 1/2013
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0900-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research

The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review

Autologous stem cells in neurology: is there a future?

Cortical control of saccades in Parkinson disease and essential tremor

In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder